23andMe sees independent board directors quit en masse

23andMe, the personal genomics company, went public in early 2021 via a merger with a blank check company that valued it at $3.5 billion. Then its fortunes began to sink. Fading interest in DNA kits – 23andMe’s main product –  was one driver. So was news last year that hackers stole ancestry data on 6.9 […]
© 2024 TechCrunch. All rights reserved. For personal use only.

Read more: https://techcrunch.com/2024/09/17/23andme-sees-independent-board-directors-quit-en-masse/

#Tech #Technology #Innovation #TechNews